IVF Treatment Process — Cost, Top Hospitals & Success Rates | MyMedicPlus

In vitro fertilisation (IVF) is a multi-step assisted reproductive technology in which eggs are retrieved from the ovaries, fertilised with sperm outside the body in a specialised embryology laboratory, and one or more resulting embryos are transferred into the uterus to establish a pregnancy. The word 'in vitro' is Latin for 'in glass,' referring to the laboratory dish (today, a small well in a culture plate) in which fertilisation occurs.

A single IVF treatment cycle takes approximately 4–6 weeks from the start of ovarian stimulation to the pregnancy test result. It comprises six distinct clinical stages:

1. Ovarian stimulation — daily hormone injections to grow multiple follicles simultaneously
2. Trigger injection — a precisely timed injection to trigger final egg maturation
3. Egg retrieval (oocyte pick-up, OPU) — a minor surgical procedure under sedation to collect eggs from the follicles
4. Fertilisation — in the embryology laboratory, either by conventional insemination or ICSI
5. Embryo culture and selection — growing embryos for 3–6 days and selecting the best for transfer
6. Embryo transfer (ET) — replacing the chosen embryo(s) into the uterine cavity

If more embryos are created than can be used in the fresh transfer, surplus good-quality embryos can be cryopreserved (vitrified) for future frozen embryo transfer (FET) cycles, making each stimulation cycle potentially yield multiple transfer attempts.

This guide covers the clinical aspects of the IVF process in detail — stimulation protocols, egg retrieval, fertilisation techniques, embryo grading, and transfer decisions. For information on who IVF is for and overall success rates, see the IVF Overview guide.

IVF is used across a wide spectrum of fertility diagnoses. Unlike simpler treatments such as IUI, IVF bypasses both the cervix and the fallopian tubes and can achieve fertilisation even when tube function is absent or severely compromised.

Tubal Factor Infertility

Blocked, damaged, or absent fallopian tubes — resulting from pelvic inflammatory disease, prior ectopic pregnancy, endometriosis, or surgical removal — prevent natural fertilisation. IVF was originally developed specifically for tubal factor infertility (the first successful IVF baby, Louise Brown, was born in 1978 to a woman with blocked tubes). It remains the definitive treatment for this indication.

Moderate to Severe Male Factor Infertility

When semen analysis reveals significantly impaired sperm count, motility, or morphology (oligoasthenoteratospermia, OAT), or when a post-wash total motile sperm count (TMSC) falls below 5–10 million, conventional IUI is unlikely to be effective. IVF — and particularly IVF with ICSI (intracytoplasmic sperm injection) — overcomes severe male factor by injecting a single sperm directly into each egg, bypassing the need for sperm to penetrate the egg independently.

Endometriosis

Moderate to severe endometriosis impairs tubal function, ovarian reserve, and the peri-ovulatory environment. IVF achieves good results even in severe endometriosis, particularly when endometriomas are managed surgically before stimulation and when long-protocol GnRH agonist downregulation is used to suppress residual disease.

Unexplained Infertility After IUI Failure

For couples with unexplained infertility who have not conceived after 3–6 stimulated IUI cycles, or where female age is 37 or above, IVF is the recommended next step (NICE NG156).

Diminished Ovarian Reserve

Women with low AMH or AFC can still achieve pregnancy through IVF, though yields per retrieval are lower and protocols must be tailored to maximise response. Donor egg IVF is considered when own-egg IVF is unlikely to produce viable embryos.

Preimplantation Genetic Testing (PGT)

IVF is required to perform preimplantation genetic testing — either for chromosomal aneuploidies (PGT-A), monogenic diseases (PGT-M, e.g. cystic fibrosis, BRCA), or structural chromosomal rearrangements (PGT-SR). Embryo biopsy is performed at Day 5–6 blastocyst stage.

A comprehensive fertility assessment must precede any IVF cycle. This determines whether IVF is the right treatment, which protocol to use, and what realistic success rates to expect.

Ovarian Reserve Testing

Anti-Müllerian hormone (AMH) — a glycoprotein secreted by pre-antral and small antral follicles — is the single most useful marker of ovarian reserve. AMH levels <1.0 ng/mL indicate diminished reserve; >3.5 ng/mL in an adult woman may indicate PCOS with associated risk of ovarian hyperstimulation syndrome (OHSS). Antral follicle count (AFC) on transvaginal ultrasound (count of follicles 2–10 mm diameter on cycle day 2–5) provides the corresponding imaging assessment. AFC and AMH together guide FSH starting dose and predict egg yield.

Uterine Assessment

A saline infusion sonogram (SIS/SHG) or hysteroscopy is performed to identify any intracavitary pathology — polyps, fibroids, or Asherman's adhesions — that would impair implantation. These should be treated before IVF begins. Endometrial thickness and morphology are assessed on baseline ultrasound.

Infectious Disease Screening

Both partners are screened for HIV (1 and 2), hepatitis B and C, syphilis, and (in some centres) HTLV-I/II. Female partners are additionally tested for rubella immunity, chlamydia, and cytomegalovirus (CMV) serostatus (for donor matching).

Semen Analysis and Sperm DNA Fragmentation

A full semen analysis (WHO 2021 criteria) is performed. Where male factor is present, a sperm DNA fragmentation (SDF) index (by TUNEL or SCSA assay) may be requested to determine whether high DNA fragmentation (>25% by TUNEL) is contributing to poor fertilisation or embryo development, guiding the decision between ICSI with testicular sperm (TESA/TESE) versus ejaculated sperm.

Karyotyping and Genetic Testing

Karyotype testing of both partners is recommended where there is a history of recurrent miscarriage, repeated IVF failure, severe OAT syndrome in the male, or known carrier status for genetic disease. Carriers of recessive or dominant conditions may be offered PGT-M to avoid transmission to offspring.

The choice of stimulation protocol is individualised based on ovarian reserve, OHSS risk, and clinical history. There is no single 'best' protocol — the optimal approach varies by patient.

GnRH Agonist Long Protocol (Downregulation + Stimulation)

The traditional 'long protocol' begins in the mid-luteal phase of the preceding cycle with daily GnRH agonist (e.g. buserelin, nafarelin nasal spray, or leuprolide acetate) to suppress endogenous LH and prevent premature ovulation. After 10–14 days of downregulation (confirmed by transvaginal ultrasound and day 2 oestradiol <200 pmol/L), FSH stimulation is added. This protocol provides excellent pituitary suppression and is preferred for women with endometriosis (ongoing agonist suppresses disease). Longer-protocol cycles are less common in current practice due to their duration (4–6 weeks total), greater medication burden, and higher OHSS risk compared with antagonist protocols.

GnRH Antagonist Protocol (Short Protocol)

Now the most widely used protocol globally. FSH injections begin on cycle day 2–3. A GnRH antagonist (cetrorelix 0.25 mg or ganirelix 0.25 mg, daily subcutaneous injections) is added from day 5–6 of stimulation (or when the lead follicle reaches 13–14 mm) to block the premature LH surge. The antagonist protocol is shorter (approximately 10–12 days total), allows flexibility in trigger timing, and — critically — allows the use of a GnRH agonist trigger instead of hCG to reduce OHSS risk in high-risk patients.

Trigger Injection: hCG vs GnRH Agonist Trigger

hCG trigger (Pregnyl 5,000–10,000 IU or Ovitrelle 250 mcg recombinant hCG) is the standard trigger, mimicking the natural LH surge and inducing final oocyte maturation. Egg retrieval is performed exactly 35–36 hours later. hCG has a long half-life (48 hours) and is associated with a higher risk of late-onset OHSS, particularly in high-responders.

GnRH agonist trigger (e.g. leuprolide 1 mg or buserelin 0.5 mg subcutaneously) can be used as an alternative in antagonist-protocol cycles. It induces a brief, self-limiting LH surge that is metabolised within 24 hours, dramatically reducing the risk of OHSS. It is the trigger of choice for high-responders and PCOS patients in a freeze-all strategy, where all embryos are vitrified and transferred in a subsequent FET cycle (avoiding the luteal phase in a fresh cycle where OHSS risk peaks).

Natural Cycle and Mini-IVF

Natural cycle IVF uses no (or minimal) stimulation drugs, collecting the single egg produced in the woman's natural cycle. Per-cycle live birth rates are low (5–8%) but costs and drug burden are minimal. Considered for women with very poor ovarian reserve where stimulation produces only 1–2 follicles anyway, or for women who cannot or will not take stimulation drugs.

Mini-IVF uses low-dose oral clomifene or low-dose FSH to collect 2–5 eggs per cycle, reducing medication cost and OHSS risk while providing more eggs than natural cycle. It is used at some clinics as a gentler alternative for poor responders or in cost-constrained settings.

Egg Retrieval (Oocyte Pick-Up, OPU)

Egg retrieval is performed as a day-case procedure under intravenous sedation (propofol, midazolam, and fentanyl is a common combination) or general anaesthesia. Using a transvaginal ultrasound probe with a needle guide attached, the fertility specialist passes a fine aspiration needle through the vaginal wall into each ovarian follicle under direct ultrasound vision, aspirating follicular fluid containing the egg. Each follicle takes approximately 30–60 seconds to aspirate. The embryologist examines the fluid immediately in the adjacent laboratory to identify and count the oocytes. The procedure takes 15–30 minutes. Post-procedure cramping and spotting are common; recovery time is typically 2–4 hours before discharge.

Fertilisation: Conventional Insemination vs ICSI

Conventional insemination: Prepared sperm are added to a culture dish containing the eggs at a density of approximately 100,000–200,000 motile sperm per egg, and the dish is incubated overnight at 37°C in 5–6% CO₂ and low-oxygen conditions. The following morning, fertilisation is confirmed by the presence of two pronuclei (2PN) — one from the egg and one from the sperm — which is the hallmark of successful fertilisation. Fertilisation rates for conventional insemination are typically 60–75%.

ICSI (intracytoplasmic sperm injection): An individual sperm is selected under high magnification, immobilised, loaded into a fine glass pipette (approximately 8 microns in diameter), and injected directly into the cytoplasm of the egg. ICSI is performed for: severe male factor infertility, previous poor fertilisation with conventional insemination, use of surgically retrieved sperm (TESA/TESE), frozen-thawed eggs (where the zona pellucida may be hardened), and PGT cycles. ICSI fertilisation rates are typically 70–85%.

Embryo Culture and Selection

Fertilised eggs (zygotes) are cultured in a time-lapse incubator (e.g. EmbryoScope) that continuously photographs the developing embryo without removing it from the controlled environment, allowing assessment of developmental kinetics. By Day 3 (cleavage stage), a normally developing embryo has 6–10 cells. By Day 5–6 (blastocyst stage), the embryo has differentiated into an inner cell mass (ICM — future baby) and a trophectoderm (TE — future placenta), surrounding a fluid-filled cavity (blastocoel).

Blastocyst culture and transfer is preferred in most modern IVF units because: it allows better embryo self-selection (only approximately 40–50% of Day-3 embryos reach blastocyst), it provides superior synchrony between embryo developmental stage and endometrial receptivity, and it improves implantation rates per transfer.

Blastocyst Grading: Gardner/Schoolcraft System

Blastocysts are graded using the Gardner and Schoolcraft (1999) system:

• Expansion score (1–6): 1 = early blastocyst (small cavity); 3 = full blastocyst (cavity >50% of volume); 4 = expanded blastocyst; 5 = hatching; 6 = hatched
• ICM grade (A, B, C): A = many tightly packed cells; B = several loosely grouped cells; C = very few cells
• TE grade (A, B, C): A = many cells forming a cohesive epithelium; B = few cells; C = very few large loose cells

A grade of 4AA (expanded blastocyst with excellent ICM and TE) is the highest quality, with published implantation rates of 40–60%. A 3BC blastocyst has a substantially lower implantation rate (~10–20%) but may still result in a healthy pregnancy.

Fresh vs Frozen Embryo Transfer (FET)

In a fresh transfer, one blastocyst (or occasionally two) is transferred on Day 5 of the same stimulation cycle. The endometrial environment during a stimulated cycle is hormonally supraphysiological (elevated oestradiol and progesterone from multiple corpora lutea), which may impair implantation relative to a natural uterine environment in some patients.

In a frozen-thawed embryo transfer (FET), surplus blastocysts are vitrified (ultra-rapid cryopreservation) after retrieval, and transferred in a subsequent cycle with careful endometrial preparation. FET survival rates for vitrified blastocysts are >95% with modern vitrification protocols. A freeze-all strategy — vitrifying all embryos from a stimulation cycle and deferring transfer — is used when OHSS risk is high (agonist trigger used), when endometrial thickness was suboptimal, or when PGT results are awaited. Large randomised trials (e.g. FROSST, ANTARCTICA) show that FET is at least equivalent to fresh transfer in live birth rates for most patients, with lower OHSS risk.

Luteal Phase Support

After embryo transfer, progesterone is administered to support the endometrium and the early pregnancy before the corpus luteum or trophoblast can maintain adequate levels independently. Vaginal progesterone pessaries (Cyclogest 400 mg twice daily or Utrogestan 200 mg three times daily) are the most widely used route in the UK. Intramuscular progesterone (progesterone in oil, 50 mg daily) is more common in the USA and achieves higher serum levels. Progesterone support continues until 8–10 weeks of gestation, after which placental progesterone production is sufficient.

IVF offers the highest per-cycle pregnancy and live birth rates of any current assisted reproductive technique and has produced over 10 million births worldwide since 1978.

Success Rates by Female Age (HFEA, 2022 UK Data)

• Under 35: approximately 32% live birth rate per embryo transfer
• 35–37: approximately 25% live birth rate per embryo transfer
• 38–39: approximately 19% live birth rate per embryo transfer
• 40–42: approximately 11% live birth rate per embryo transfer
• Over 42 (own eggs): approximately 5% live birth rate per embryo transfer

These rates reflect all cycles reported to the HFEA (including both fresh and frozen transfers) and include outcomes from patients with diverse diagnoses. Success rates at individual clinics may differ depending on case mix, embryo selection policy, and reporting methodology.

Cumulative Live Birth Rate

Cumulative live birth rates — accounting for all embryos generated from a single stimulation cycle, including subsequent FET cycles — are substantially higher than per-transfer rates. For a woman under 35 producing, for example, 4 usable blastocysts from one retrieval, the cumulative live birth rate may exceed 60–70% across all transfers.

Embryo Cryopreservation

Surplus high-quality embryos that are vitrified can remain viable for many years. HFEA regulations currently permit storage for up to 10 years (extendable to 55 years in some circumstances). This means one stimulation cycle can support multiple future pregnancy attempts without repeat egg retrieval.

Genetic Testing (PGT-A)

When IVF is combined with PGT-A, only chromosomally normal (euploid) embryos are transferred, reducing miscarriage risk (from approximately 25–30% with unscreened transfer to ~5–10% with euploid FET) and potentially reducing the number of transfer cycles needed to achieve a live birth. The benefit is most pronounced for women over 37, where the proportion of aneuploid embryos increases significantly.

IVF carries a number of well-characterised risks that must be discussed in the context of the individual patient's clinical profile.

Ovarian Hyperstimulation Syndrome (OHSS)

OHSS is the most significant medical complication of IVF ovarian stimulation. It results from excessive ovarian response to FSH, producing multiple follicles and a marked rise in vascular endothelial growth factor (VEGF), causing fluid shifts from the intravascular space into body cavities. Mild OHSS (bloating, mild discomfort, ovaries <8 cm) occurs in 20–33% of stimulated cycles. Moderate OHSS (nausea, vomiting, ultrasound-confirmed ascites) in 3–6%. Severe OHSS (haemoconcentration, electrolyte disturbance, thromboembolism risk, hospitalisation required) in <1–2%. Risk factors include PCOS, young age, high AFC, and high AMH. The most effective prevention strategies are: GnRH antagonist protocol + agonist trigger (replaces hCG trigger) followed by freeze-all, and elective freeze-all cycles (no fresh transfer) to avoid the OHSS-amplifying effect of early pregnancy beta-hCG.

Multiple Pregnancy

IVF multiple pregnancy rates have fallen dramatically with the widespread adoption of elective single embryo transfer (eSET). In the UK, the multiple birth rate from IVF fell from 24% in 2009 to under 6% by 2022 (HFEA data), approaching the goal of <10%. Twin pregnancies remain the most significant IVF-associated risk for mothers and babies: preterm birth rate in IVF twins is 50% vs 6% in singletons; perinatal mortality is 4-fold higher. Patients should be counselled that transferring one embryo at a time — even if slightly reducing per-transfer pregnancy rate — is safer for both mother and baby.

Egg Retrieval Complications

Vaginal bleeding from the puncture sites (<0.5%), pelvic infection (<0.5%), inadvertent bladder or bowel puncture (rare), and anaesthetic complications. Overall, egg retrieval is a very safe procedure with a major complication rate well under 1%.

IVF Add-Ons: HFEA Traffic Light System

A wide range of 'add-on' procedures and supplements are marketed by fertility clinics as potentially improving IVF outcomes. The HFEA (Human Fertilisation and Embryology Authority) rates these using an evidence traffic light system (red, amber, green) based on available randomised trial evidence:

• ERA (Endometrial Receptivity Analysis/Array): AMBER — some studies show benefit in women with repeated implantation failure; not recommended for routine use. Current RCT data (IVIRMA 2023) did not show significant benefit in an unselected population.
• EMMA/ALICE (uterine microbiome testing): AMBER — theoretically sound; RCT evidence insufficient to recommend routinely; may be appropriate for selected cases of recurrent implantation failure.
• PGT-A (preimplantation genetic testing for aneuploidies): AMBER — reduces per-transfer miscarriage rate and may reduce number of transfers needed for live birth; does not increase cumulative live birth rate in most populations under 37. Evidence strongest in women over 37 and those with recurrent miscarriage.
• Intralipid infusion: RED — insufficient evidence; not recommended outside research protocols.
• Endometrial scratch: RED — large RCTs (ISRCTN, Scratch, and BIGscore trials) showed no benefit over no-scratch; previously widely offered, now not recommended.
• Time-lapse imaging (EmbryoScope): AMBER — improves embryo observation without interrupting culture; whether kinetic parameters improve selection over morphology alone remains debated; low risk of harm.

After embryo transfer, patients enter the 'two-week wait' before the pregnancy test. This period requires both clinical management and emotional support.

Luteal Phase Management

Vaginal progesterone (or intramuscular, as prescribed by the clinic) continues until the pregnancy test. Activities are not required to be restricted — complete bed rest after transfer has been shown in randomised trials to offer no benefit over normal activity and may be detrimental to patient wellbeing. Intercourse is generally permitted but many patients prefer to avoid it during the two-week wait.

Pregnancy Test (Beta-hCG)

A serum beta-hCG test is performed 14 days after the day of egg retrieval (in a fresh cycle) or 14 days after the FET. A rising beta-hCG (repeat test at 48 hours showing approximately doubling) indicates ongoing early pregnancy. A viability ultrasound scan is performed at 6–7 weeks gestation to confirm foetal heartbeat(s) and the number of gestational sacs.

Continuing Pregnancy Care

For a successful IVF pregnancy, progesterone support continues until 8–10 weeks gestation (when the placenta takes over progesterone production). From 12 weeks, care transitions to standard antenatal care. IVF pregnancies are considered high-risk in some healthcare systems, warranting closer monitoring for gestational diabetes, hypertensive disorders, and pre-term birth, even with singleton pregnancies.

Failed Cycles: Review and Next Steps

After a failed embryo transfer — whether no implantation occurred or an early miscarriage was confirmed — a structured review appointment is essential. The clinical team should assess: embryo quality data, endometrial thickness, transfer ease, and any symptoms during the two-week wait. For women with surplus cryopreserved embryos, a FET cycle can typically be scheduled within 1–3 months. Women who have experienced 3 or more failed embryo transfers despite good embryo quality should be offered investigation for recurrent implantation failure (RIF): uterine reassessment, thrombophilia screen, immunological evaluation, and a second opinion at a specialised reproductive immunology unit if appropriate.

IVF costs vary substantially between countries, between NHS and private provision, and between clinics within each sector.

NHS Funding (England)

NICE NG156 recommends that NHS Integrated Care Boards (ICBs) fund up to 3 full IVF cycles for eligible women under 40 who have not previously had IVF. In practice, NHS IVF funding varies dramatically across England — many ICBs fund only 1 cycle, some have restricted eligibility to women under 35 or 38, and a significant number have suspended IVF funding entirely during NHS financial pressures. Patients must check their local ICB's current fertility funding policy, as it changes frequently.

Private Costs (United Kingdom)

A single private IVF cycle — including monitoring scans, anaesthetic, egg retrieval, embryology, and one fresh embryo transfer — typically costs £5,000–£8,000 at UK private clinics. Medications (FSH, antagonist, trigger, progesterone) add £1,000–£2,500 depending on dose required. Add-ons (PGT-A, ERA, time-lapse) each add £500–£3,000. A FET cycle costs approximately £1,500–£3,000 plus medication. Total cost of a stimulation cycle with PGT-A and one FET can easily reach £10,000–£15,000 at a UK private clinic.

International Costs

• Spain: €4,000–€6,000 per cycle; widely used by international patients due to liberal donor regulations and high-quality IVF programmes
• Czech Republic: €2,500–€4,500 per cycle; a major medical tourism destination for IVF with high success rates
• India (NABH-accredited clinics): ₹80,000–₹1,50,000 per cycle (approximately $1,000–$1,800)
• USA: $15,000–$25,000 per cycle including medications; significant variation by state and clinic
• Greece: €3,000–€5,000; popular with northern European patients

Finance Options

Many UK private clinics offer multi-cycle packages (typically 2–3 cycles at a discounted bundled price) and refund programmes (a higher upfront fee with a partial refund if a live birth is not achieved within the agreed number of cycles). These schemes require careful scrutiny of eligibility criteria, exclusion clauses, and the long-term financial model of the clinic offering them.

Several modifications and alternatives to standard IVF exist for patients in whom the conventional approach is unsuitable, unsuccessful, or unacceptable.

IUI (Intrauterine Insemination)

For couples with unexplained infertility, mild male factor, or cervical factor who have not yet tried IUI, it remains a less invasive and less expensive first step. Its per-cycle success rate is lower than IVF but cumulative success over 3–6 cycles is comparable for appropriate patients under 37 (see IUI Treatment guide).

Natural Cycle IVF

For women who cannot tolerate injectable FSH, have very poor ovarian reserve where stimulation adds no benefit, or who hold ethical objections to the possibility of surplus embryo creation, natural cycle IVF collects the single naturally selected egg each month. Per-cycle live birth rates are substantially lower than stimulated IVF, but multiple cycles can be attempted in consecutive months with minimal drug side effects.

Mini-IVF (Minimal Stimulation IVF)

Low-dose stimulation with clomifene (oral) +/- low-dose FSH aims for 2–5 eggs rather than the 10–15 typical of conventional stimulation. Medication costs are lower; OHSS risk is minimal. Evidence suggests mini-IVF has lower per-cycle success rates than conventional IVF for normal and good responders, but may be appropriate for poor responders and cost-constrained patients.

Donor Egg IVF

For women with very low ovarian reserve (AMH <0.5 ng/mL), premature ovarian insufficiency, poor embryo quality despite multiple stimulation cycles, or advanced female age (typically over 43–45), donor egg IVF using eggs from a young screened donor achieves live birth rates of 40–55% per embryo transfer, independent of recipient age. This is the most effective single intervention for overcoming age-related infertility.

Embryo Donation (Double Donation)

Couples who cannot use their own eggs or sperm may receive donated embryos created from donor egg and donor sperm from unrelated donors. This is the most affordable form of third-party reproduction and achieves pregnancy rates comparable to donor egg IVF, but involves no genetic connection to either intended parent.

Preimplantation Genetic Testing Modifications

For patients with a history of recurrent miscarriage or specific genetic conditions, IVF combined with PGT-M (for monogenic diseases) or PGT-SR (for chromosomal rearrangements) modifies the standard IVF cycle to select embryos free from specific genetic diseases or unbalanced chromosomal arrangements, significantly reducing the risk of an affected pregnancy.